Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Receivables (2016 - 2025)

Historic Receivables for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $10.4 million.

  • Cumberland Pharmaceuticals' Receivables fell 778.05% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 778.05%. This contributed to the annual value of $11.7 million for FY2024, which is 1991.45% up from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Receivables is $10.4 million, which was down 778.05% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Receivables registered a high of $15.2 million during Q3 2022, and its lowest value of $6.9 million during Q4 2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' median Receivables value was $11.6 million (recorded in 2024), while the average stood at $11.6 million.
  • Within the past 5 years, the most significant YoY rise in Cumberland Pharmaceuticals' Receivables was 11091.57% (2021), while the steepest drop was 4443.77% (2021).
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Receivables stood at $6.9 million in 2021, then soared by 91.41% to $13.2 million in 2022, then decreased by 25.87% to $9.8 million in 2023, then grew by 19.91% to $11.7 million in 2024, then decreased by 10.86% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $10.3 million for Q2 2025, and $10.5 million during Q1 2025.